LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02105 LAEKNA-B

Trading 05-12 14:17:45

13.670

-1.350

-8.99%

High15.080	Low13.600	Vol3.39M
Open15.080	D1 Closing15.020	Amplitude9.85%
Mkt Cap6.14B	Tradable Cap6.14B	Total Shares449.00M
T/O47.62M	T/O Rate0.76%	Tradable Shares449.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"LAEKNA-B","latestPrice":13.67,"timestamp":1778566656981,"preClose":15.02,"halted":0,"volume":3392400,"delay":0,"changeRate":-0.08988015978695071,"floatShares":449000000,"shares":449000000,"eps":-0.6799588229307739,"marketStatus":"Trading","change":-1.35,"latestTime":"05-12 14:17:45","open":15.08,"high":15.08,"low":13.6,"amount":47624644,"amplitude":0.098535,"askPrice":13.69,"askSize":4500,"bidPrice":13.67,"bidSize":25000,"shortable":3,"etf":0,"ttmEps":-0.6557568987247633,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778573400000},"marketStatusCode":2,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":15.02,"openAndCloseTimeList":[[1778549400000,1778558400000],[1778562000000,1778572800000]],"volumeRatio":1.817096,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105/wiki","defaultTab":"wiki","newsList":[{"id":"1179222950","title":"Stock Track | LAEKNA-B Plummets 8.59% Intraday Amid Insider Selling Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1179222950","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179222950?lang=en_us&edition=fundamental","pubTime":"2026-05-12 13:40","pubTimestamp":1778564440,"startTime":"0","endTime":"0","summary":"LAEKNA-B stock experienced a significant decline, plummeting 8.59% during intraday trading on Tuesday.The sharp drop appears to be linked to investor reaction following news of insider selling...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634125263","title":"Laekna Sees Insider Stock Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=2634125263","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634125263?lang=en_us&edition=fundamental","pubTime":"2026-05-12 10:40","pubTimestamp":1778553610,"startTime":"0","endTime":"0","summary":"Looking at Laekna, Inc.'s ( HKG:2105 ) insider transactions over the last year, we can see that insiders were net...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/laekna-sees-insider-stock-selling","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/laekna-sees-insider-stock-selling","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122306758","title":"LAEKNA-B Shares Surge Over 10% in Afternoon Trading as Qilu Pharmaceutical Advances LAE002 NDA; Company Poised for Upfront and Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=1122306758","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122306758?lang=en_us&edition=fundamental","pubTime":"2026-05-11 14:48","pubTimestamp":1778482108,"startTime":"0","endTime":"0","summary":"LAEKNA-B shares surged over 10% in afternoon trading. As of the latest update, the stock was up 9.63%, trading at HKD 14.8 with a turnover of HKD 60.8913 million. On April 15, the company formally...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IPOS","BK4585","BK1191","BK1161","VXUS","BK1574","02105","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634750364","title":"Laekna Grants Restricted Share Units to Directors, Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2634750364","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634750364?lang=en_us&edition=fundamental","pubTime":"2026-05-11 11:12","pubTimestamp":1778469175,"startTime":"0","endTime":"0","summary":"Laekna  said it granted 15.3 million restricted share units to three executive directors and employees, according to a Friday filing with the Hong Kong bourse.The drug company's shares gained nearly 5% in morning trade Monday.Of the total, 7.7 million RSUs were earmarked for employees, while an additional 2.6 million RSUs were granted to Lu Chris Xiangyang, Gu Xiang-Ju Justin, and Xie Ling.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118194217","title":"LAEKNA-B Issues 2.865 Million Shares to Fulfill RSU Vesting Under 2024 Share Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1118194217","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118194217?lang=en_us&edition=fundamental","pubTime":"2026-05-11 08:10","pubTimestamp":1778458217,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that on May 8, 2026, the company issued a total of 2.865 million ordinary shares to satisfy the vesting of Restricted Share Units (RSUs) granted under the 2024 Share Incentive Plan.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146832932","title":"Laekna-B Issues 2.87 Million New Shares for 2024 RSU Vesting, Lifting Share Base to 449.33 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1146832932","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146832932?lang=en_us&edition=fundamental","pubTime":"2026-05-11 08:03","pubTimestamp":1778457785,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (Laekna-B) reported a 0.64% expansion in its share capital after issuing 2.87 million new ordinary shares on 8 May 2026 to satisfy restricted stock unit (RSU) vesting under the company’s...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634422925","title":"Laekna files HKEX next-day return, issues 2.87 million shares at HKD 0","url":"https://stock-news.laohu8.com/highlight/detail?id=2634422925","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634422925?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:59","pubTimestamp":1778457597,"startTime":"0","endTime":"0","summary":"Laekna filed next-day disclosure return dated May 11, 2026 covering share issuance on May 8, 2026 under 2024 share award plan RSU vesting.Issued 2,865,000 new ordinary shares at HKD 0 per share.Issued share capital rose to 449,331,350 ordinary shares from 446,466,350.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nNDL7k5MnF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163365766","title":"Laekna Grants 15.32 Million RSUs; Director Awards Require Shareholder Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=1163365766","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163365766?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:43","pubTimestamp":1778240631,"startTime":"0","endTime":"0","summary":"Laekna-B has approved the issuance of 15.32 million restricted share units (RSUs) under its 2024 Share Award Scheme, according to a board announcement dated 8 May 2026. Key grant parameters   •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176480621","title":"LAEKNA-B (02105) Grants 15.3235 Million Restricted Share Units in Total","url":"https://stock-news.laohu8.com/highlight/detail?id=1176480621","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176480621?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:39","pubTimestamp":1778240345,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that on May 8, 2026, a total of 15.3235 million restricted share units, equivalent to 15.3235 million shares, were granted to recipients under the 2024 Share Award Scheme....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145594989","title":"LAEKNA-B Shares Surge Over 5% in Late Trading as Qilu Pharma Advances Domestic Application for LAE002","url":"https://stock-news.laohu8.com/highlight/detail?id=1145594989","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145594989?lang=en_us&edition=fundamental","pubTime":"2026-05-07 15:26","pubTimestamp":1778138779,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) saw its shares rise more than 5% in late trading. As of the time of writing, the stock was up 3.83%, trading at HK$13.82 with a turnover of HK$25.91 million. On April 30, Qilu...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1191","BK1161","01477","02105","VXUS","IPOS","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179282629","title":"Laekna-B Keeps Share Base Unchanged in April 2026; Public Float Remains Above 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179282629","media":"Bulletin Express","labels":["shareholding","SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179282629?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:23","pubTimestamp":1778059434,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (abbrev. Laekna-B) reported no changes to its share capital structure for the month ended 30 April 2026, according to the company’s monthly return filed with Hong Kong Exchanges and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150443811","title":"Revised Title","url":"https://stock-news.laohu8.com/highlight/detail?id=1150443811","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150443811?lang=en_us&edition=fundamental","pubTime":"2026-04-20 09:56","pubTimestamp":1776650198,"startTime":"0","endTime":"0","summary":"CICC Maintains Outperform Rating on LAIKNA-B (02105) with HK$27.02 Target Price","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","EWH","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627477078","title":"Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627477078","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627477078?lang=en_us&edition=fundamental","pubTime":"2026-04-15 12:34","pubTimestamp":1776227646,"startTime":"0","endTime":"0","summary":"Laekna  said its LAE002 oral drug met the primary endpoint of progression-free survival in a phase 3 clinical trial, according to a Hong Kong bourse filing Wednesday.Results from the FFIRM-205 study showed that a combination of LAE002 and fulvestrant achieved a progression-free survival of 7.6 months in subjects with breast cancer, compared with two months for fulvestrant alone.The firm has a China licensing agreement with Qilu Pharmaceutical for LAE002 under which it is eligible to receive up to 2.05 billion yuan in total upfront and milestone payments.The firm said it will submit a new drug application for LAE002 in China in the \"near term.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103233133","title":"LAEKNA-B's Afuresertib Meets Primary Endpoint in Phase III Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1103233133","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103233133?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:26","pubTimestamp":1776212787,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that its Phase III clinical trial, AFFIRM-205, evaluating LAE 002 (afuresertib) in combination with fulvestrant, has achieved strong positive topline results. The trial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK4211","BK4195","III","BK4134","BK1161","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473859","title":"Laekna says phase III afuresertib breast cancer trial meets PFS endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473859","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627473859?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:15","pubTimestamp":1776212144,"startTime":"0","endTime":"0","summary":"Laekna reported positive topline Phase III results for LAE002  with fulvestrant in HR+/HER2- locally advanced or metastatic breast cancer patients with PIK3CA/AKT1/PTEN alterations.Trial met primary endpoint, showing a clinically meaningful delay in disease progression versus control.Safety profile remained consistent with earlier studies, with low treatment discontinuation due to adverse events.Detailed results will be presented at a future international scientific conference.Laekna plans near-term NDA submission in China with Qilu Pharma, supported by a China license deal worth up to RMB 2 billion in upfront and milestone payments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3vC8Qj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163097580","title":"莱凯医药2025年实现首笔收入并稳步推进ActRII管线，研发投入上升净亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1163097580","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163097580?lang=en_us&edition=fundamental","pubTime":"2026-04-13 17:45","pubTimestamp":1776073500,"startTime":"0","endTime":"0","summary":"莱凯医药（于香港联交所主板上市，股票简称“LAEKNA-B”，股份代号02105）公布截至2025年12月31日止年度业绩，首次录得收入人民币1.067亿元（2024年无收入），主要来自向本地医药企业对LAE002（afuresertib）的许可交易。同期成本为人民币0.203亿元，毛利达人民币0.864亿元，毛利率为81.0%。研发开支同比增长16.2%至人民币2.499亿元，主要投向ActRI...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627436753","title":"Laekna publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2627436753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627436753?lang=en_us&edition=fundamental","pubTime":"2026-04-13 17:28","pubTimestamp":1776072502,"startTime":"0","endTime":"0","summary":"Laekna published 2025 annual report dated March 18, 2026, highlighting pipeline progress in obesity and oncology programs.Phase I SAD and MAD studies of LAE102 in China completed in 2025, supporting continued development as muscle-preserving weight-control therapy.LAE102 Phase I SAD study in US completed with Eli Lilly in March 2026, showing dose-dependent lean mass gains.Phase III AFFIRM-205 trial in China for LAE002 afuresertib with fulvestrant completed enrollment in December 2025, with topline data targeted in first half of 2026.Exclusive China-region license for LAE002 granted to Qilu Pharma, including milestone payments up to RMB 2.045 billion plus tiered royalties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. publi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL4s28Gj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1127390331.HKD","02105","LU0006306889.USD","IE00B1BXHZ80.USD","LU1551013425.SGD","LU0354030438.USD","LU2213496289.HKD","LU2112291526.USD","GB00BDT5M118.USD","LU0079474960.USD","LU0210536198.USD","LU1064131342.USD","LU2237443622.USD","LU1035775433.USD","LU2108987350.USD","SG9999014880.SGD","LU1623119135.USD","BK1161","LU1093756325.SGD","IE00B4JS1V06.HKD","LU2746668974.SGD","LU2361045086.USD","SG9999015952.SGD","LU2023250504.SGD","LU2168564149.EUR","LU0882574139.USD","LU2237443382.USD","SG9999014898.SGD","SG9999017495.SGD","SGXZ31699556.SGD","IE00BKPKM429.USD","LU2168564495.EUR","LU0061475181.USD","LU0456855351.SGD","LU2491049909.HKD","IE00BJJMRZ35.SGD","IE0001KFT4U8.USD","LU0256863811.USD","LU1093756168.USD","LU1366192091.USD","LU1629891620.HKD","LU2750360997.AUD","ELIL","LU2552382215.SGD","LU2417539215.USD","LU0471298777.SGD","BK4581","LU2468319806.SGD","LU2602419157.SGD","LU0094547139.USD","LU1814569148.SGD","SG9999015986.USD","LU2264538146.SGD","IE0009355771.USD","LU2896262040.SGD","LU2756315318.SGD","LU0256863902.USD","IE00BJJMRX11.SGD","LU1917777945.USD","LU2746668461.USD","LU2756315664.SGD","BK4516","LU2357305700.SGD","LU2089284900.SGD","LU0466842654.USD","LU0158827948.USD","IE00BWXC8680.SGD","LU2237443978.SGD","LU1267930730.SGD","LU0823434740.USD","LU2236285917.USD","LU2063271972.USD","LU2461242641.AUD","LU0320765059.SGD","LU2111349929.HKD","SG9999001176.SGD","SG9999018857.SGD","SG9999001176.USD","BK4533","IE00B1XK9C88.USD","LU0820562030.AUD","IE00BJT1NW94.SGD","LU2265009873.SGD","LU0109391861.USD","LU0158827781.USD","LU2237443895.HKD","SG9999014914.USD","IE0002141913.USD","LU1988902786.USD","LU1712237335.SGD","LU0198837287.USD","LU1804176565.USD","LU0203202063.USD","LU0096364046.USD","LU2237438978.USD","LU0106261372.USD","LU0823434583.USD","LU0708995401.HKD","LU2491050071.SGD","IE00BK4W5L77.USD","LU0238689110.USD","LU0354030511.USD","LU1974910355.USD","LU0320765992.SGD","LU2361044865.SGD","IE00BK4W5M84.HKD","SGXZ57979304.SGD","LU0289739699.SGD","LU1291159041.SGD","LU2271345857.HKD","LU0234572021.USD","IE00BFSS8Q28.SGD","LU2023251221.USD","LU0683600562.USD","LU1868837300.USD","LU2237443465.HKD","BK4585","LU2360106947.USD","LU2456880835.USD","LLII","LU0820561909.HKD","LU2750360641.GBP","LU0058720904.USD","SG9999015945.SGD","LU2361044949.HKD","LU2106854487.HKD","IE0004445239.USD","LU0943347566.SGD","LLYX","LU1983299246.USD","BK4007","LU1280957306.USD","LU0417517546.SGD","LU1069344957.HKD","SG9999015978.USD","IE00BFSS7M15.SGD","LU1720051017.SGD","LU0672654240.SGD","IE00BKDWB100.SGD","IE0004445015.USD","LU0114720955.EUR","LU0882574055.USD","LU1145028129.USD","LU2471134879.HKD","LU2471134523.USD","LU2237443549.SGD","IE00BN29S564.USD","LU0889565916.HKD","LU0353189680.USD","LU0786609619.USD","SGXZ51526630.SGD","SGXZ81514606.USD","LU1548497426.USD","LU2168564065.EUR","SG9999018865.SGD","LU0109394709.USD","LU2028103732.USD","LU2462157665.USD","LU1989771016.USD","LU2552382132.HKD","SG9999013999.USD","LU1023059063.AUD","LU1061106388.HKD","LU1868836591.USD","LU0122379950.USD","LU2168563687.JPY","LU0203201768.USD","IE00B7KXQ091.USD","LU0097036916.USD","LU1720051108.HKD","LU2471134796.USD","LU0820561818.USD","LU2324357040.USD","LU1868836757.USD","BK4599","LU2089984988.USD","LU0689472784.USD","IE00BJJMRY28.SGD","LLYZ","ELIS","LU0385154629.USD","SG9999014906.USD","BK4534","LU1057294990.SGD","LU2023250330.USD","LU2552382058.USD","LU1868837136.USD","LU0640476718.USD","LU0787776722.HKD","BK4588","LU1232071149.USD","LU0353189763.USD","IE00BFTCPJ56.SGD","IE0005OL40V9.USD","IE00BJLML261.HKD","LU0316494557.USD","LU0471298694.HKD","LU1551013342.USD","LU2211815571.USD","LU2087625088.SGD","SGXZ99366536.SGD","LU2491050154.USD","LU0432979614.USD","LU1323610961.USD","LU2168564222.USD","LU0225283273.USD","LU1868836914.USD","LU0823416689.USD","LU2089283258.USD","LU0964807845.USD","IE00B775H168.HKD","IE00B4R5TH58.HKD","LU2471134952.CNY","IE00B2B36J28.USD","LU0323591593.USD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197564420","title":"Weight-Loss Drug Market Competition Intensifies as Laekna's LAE102 Shows Superior Clinical Data Over Small RNA Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1197564420","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197564420?lang=en_us&edition=fundamental","pubTime":"2026-04-09 11:23","pubTimestamp":1775704981,"startTime":"0","endTime":"0","summary":"Laekna's core product LAE102 has demonstrated outstanding muscle-building effects and safety in its US Phase I clinical trial, surpassing small RNA-based weight-loss drug pipelines that have recently...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185906956","title":"Laekna-B Maintains 446.47 Million Outstanding Shares in March; No Capital Changes Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=1185906956","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185906956?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:27","pubTimestamp":1775122027,"startTime":"0","endTime":"0","summary":"For the month ended 31 March 2026, Laekna-B (Laekna, Inc.) reported zero movement in both authorised and issued share capital. Authorised Share Capital   • Total authorised shares remained at 5.00...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620025065","title":"BRIEF-Laekna Posts FY Revenue Rmb106.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620025065","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620025065?lang=en_us&edition=fundamental","pubTime":"2026-03-18 23:29","pubTimestamp":1773847744,"startTime":"0","endTime":"0","summary":"BRIEF-Laekna Posts FY Revenue Rmb106.7 MillionMarch 18 (Reuters) - Laekna Inc 2105.HK:FY REVENUE RMB106.7 MILLIONLOSS FOR YEAR RMB229.3 MILLIONFurther company coverage: 2105.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.09},{"period":"1month","weight":-0.1628},{"period":"3month","weight":0.194},{"period":"6month","weight":0.2838},{"period":"1year","weight":0.0081},{"period":"ytd","weight":0.1069}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0198},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0192},{"period":"1year","weight":0.1548},{"period":"ytd","weight":0.0303}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.264392},{"month":2,"riseRate":0.666667,"avgChangeRate":0.234103},{"month":3,"riseRate":0.666667,"avgChangeRate":0.090739},{"month":4,"riseRate":0.333333,"avgChangeRate":0.001974},{"month":5,"riseRate":1,"avgChangeRate":0.142268},{"month":6,"riseRate":0,"avgChangeRate":-0.12904},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.063454},{"month":8,"riseRate":0.666667,"avgChangeRate":0.069227},{"month":9,"riseRate":0.666667,"avgChangeRate":0.04052},{"month":10,"riseRate":0.666667,"avgChangeRate":0.10793},{"month":11,"riseRate":1,"avgChangeRate":0.401946},{"month":12,"riseRate":0,"avgChangeRate":-0.176326}],"exchange":"SEHK","name":"LAEKNA-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LAEKNA-B,02105,LAEKNA-B股票,LAEKNA-B股票老虎,LAEKNA-B股票老虎国际,LAEKNA-B行情,LAEKNA-B股票行情,LAEKNA-B股价,LAEKNA-B股市,LAEKNA-B股票价格,LAEKNA-B股票交易,LAEKNA-B股票购买,LAEKNA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}